Clinical Trials
18 trialsNCT07394062 2026-05-18
ALCG-01
Gazi University
Recruiting
NCT07192926 2026-02-20
SARCO-CTI
Ankara Etlik City Hospital
Completed
NCT04557007 2026-01-29
Oncomabs
Oslo University Hospital
Terminated
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT06607393 2024-09-23
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
Aetion, Inc.
Completed
NCT06585189 2024-09-05
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
Aetion, Inc.
Completed
NCT06532149 2024-08-09
EROS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT04291755 2024-04-05
Development and Analysis of a Stool Bank for Cancer Patients
Persephone Biosciences
Recruiting
NCT05418660 2023-09-18
I-STOP
University of Milano Bicocca
Unknown
NCT05908799 2023-09-13
Emulation of the KEYNOTE-189 Trial Using Electronic Health Records
Aetion, Inc.
Completed
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT05023837 2022-01-25
Esporta
Hunan Province Tumor Hospital
Completed
NCT04465942 2021-08-23
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
European Lung Cancer Working Party
Unknown
NCT04860076 2021-04-26
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
Unknown
NCT03373955 2021-03-18
A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients
Sichuan University
Unknown
NCT04076228 2020-09-02
Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients
Kiang Wu Hospital
Completed
NCT03695835 2020-07-22
NIRPA
Gary Onik MD
Completed
NCT04115410 2020-05-28
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Unknown